Marie Zhang, PhD, Vice President of Research and Clinical Development at Imagion Biosystems, presented the poster “HER2 Functionalized Nanoparticles Are Safe and Specific for in
On Saturday, December 8, 2018, Marie Zhang, PhD presented the poster “Detection of HER2 Positive Tumor Cells Using Functionalized Iron Oxide Nanoparticles” at the 2018
The ASCO 2018 Annual Meeting abstract, “Detection and measurement of HER2+ breast cancer cells using tumor-targeted iron oxide nanoparticles and magnetic relaxometry” is now available
Pre-clinical data on Imagion Biosystems’ MagSense HER2+ cancer detection platform have shown: specific binding and detection of HER2+ tumor cells in vitro specific detection of
Imagion Biosystems’ abstract “Detection of HER2+ tumor cells using MagSense® nanoparticles: safety and sensitivity” has been accepted for the 2018 AACR meeting under the organization’s
The 2017 International Convention of BIO, the Biotechnology Innovation Organization, was held June 19-22 in San Diego. More than 16,000 individuals attended BIO 2017, including
On June 5, 2017, Imagion Biosystems Chief Scientist Erika Vreeland, PhD, presented the results of a collaborative tumor detection study to the scientific audience assembled
This year’s Annual Meeting of the American Association for Cancer Research was held April 1-5 in Washington, D.C. The theme of this year’s meeting was
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance